| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Chief Financial Officer
1 company
Cline Christopher R. is a Chief Financial Officer at Travere Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 9 sells.
Estimated insider holdings value: $5.0M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 2024 | TVTX Travere Therapeutics, Inc. | Chief Financial Officer | Sell | 514 | $9.51 | $4,887.78 | -0.7% | +92.8% | +110.4% | |
| Apr 11, 2024 | TVTX Travere Therapeutics, Inc. | Chief Financial Officer | Sell | 54 | $6.74 | $363.96 | - | +42.5% | +116.7% | |
| Feb 1, 2024 | TVTX Travere Therapeutics, Inc. | Chief Financial Officer | Sell | 3,818 | $8.53 | $32,572.50 | -5.1% | -30.2% | +137.9% | |
| Jan 23, 2024 | TVTX Travere Therapeutics, Inc. | Chief Financial Officer | Sell | 853 | $9.07 | $7,735.35 | -1.7% | -37.0% | +109.5% | |
| Sep 5, 2023 | TVTX Travere Therapeutics, Inc. | Chief Financial Officer | Sell | 457 | $14.71 | $6,722.56 | -0.9% | -55.7% | -29.2% | |
| May 10, 2023 | TVTX Travere Therapeutics, Inc. | Chief Financial Officer | Sell | 455 | $16.59 | $7,548.45 | -0.9% | -4.8% | -59.5% | |
| Apr 11, 2023 | TVTX Travere Therapeutics, Inc. | Chief Financial Officer | Sell | 47 | $21.49 | $1,010.03 | - | -25.8% | -68.2% | |
| Feb 1, 2023 | TVTX Travere Therapeutics, Inc. | Chief Financial Officer | Sell | 1,588 | $21.75 | $34,542.18 | -3.0% | -29.2% | -61.1% | |
| Jan 24, 2023 | TVTX Travere Therapeutics, Inc. | Chief Financial Officer | Sell | 852 | $21.90 | $18,662.55 | -2.5% | -2.9% | -58.3% |